This implicitly implies that the role of the RAS in the formation of lung cancer is complicated and that ACEI/ARB medication may have an impact on lung cancer development via additional pathways, such as the buildup of substance P in the lungs due to ACEI usage. The gene discussed is TAC1; the disease is lung cancer.